

1 **CHALLENGED IMMUNE SYSTEM IMPROVES COGNITIVE-BEHAVIORAL**
2 **RESPONSES IN HOMEOSTASIS AND RECOVERS MALARIA-INDUCED**
3 **COGNITIVE IMPAIRMENT IN MICE**

4
5 *Luciana Pereira de Sousa*[#], *Flávia Lima Ribeiro-Gomes*[#], *Roberto Farina de*
6 *Almeida*^{***}, *Tadeu Mello e Souza*^{**}, *Guilherme Loureiro Werneck*^{***}, *Diogo Onofre*
7 *Gomes de Souza*^{**} & *Cláudio Tadeu Daniel-Ribeiro*^{*1}

8
9 **Laboratório de Pesquisa em Malária, Instituto Oswaldo Cruz & Centro de Pesquisa, Diagnóstico e*
10 *Treinamento em Malária (CPD-Mal) of Fundação Oswaldo Cruz (Fiocruz) and of Secretaria de*
11 *Vigilância em Saúde (SVS), Ministério da Saúde; **Departamento de Bioquímica, Universidade*
12 *Federal do Rio Grande do Sul and *** Departamento de Epidemiologia of the Instituto de Medicina*
13 *Social, Universidade do Estado do Rio de Janeiro and Instituto de Estudos de Saúde Coletiva da*
14 *Universidade Federal do Rio de Janeiro, Brazil.*

15
16 ¹Corresponding author at : *Laboratório de Pesquisa em Malária, Instituto Oswaldo Cruz, Fiocruz. Av.*
17 *Brasil 4365, Manguinhos, Rio de Janeiro. CEP 2104-360, RJ Brazil. E-mail malaria@fiocruz.br*

18 [#] These authors contributed equally to the work

19 ⁺ Present address: *Programa de Pós-Graduação em Ciências Biológicas, Instituto de Ciências Exatas*
20 *e Biológicas, Universidade Federal de Ouro Preto, Minas Gerais, Brazil*

21
22 **ABSTRACT**

23 The immune and nervous systems can be categorized as cognitive plastic systems for
24 their ability to know and recognize “real world objects”, including microbes, and
25 because of their prerogative of constant self-reorganization as they live learning
26 experiences. After each antigenic or sensory occurrence, vertebrate organisms
27 experience changes in the cellular connections of their immune and nervous systems
28 altering their abilities and structures. Elements of the immune machinery are necessary
29 for neurocognitive function, and the pattern of the immune response triggered by
30 different stimuli may induce regulator or deregulator signals for the nervous functions.
31 Here we show, for the first time, that the immune modulation with anti-inflammatory
32 stimuli can positively regulate the behavior of healthy mice and mitigate the cognitive-
33 behavioral deficits induced by a mild infection of C57BL/6 animals with *Plasmodium*
34 *berghei* ANKA.

35
36 **INTRODUCTION**

37 There is considerable evidence for the existence of strong interactions between the immune and
38 nervous cognitive systems¹⁻⁷. Immunomodulation of the nervous system does exist and can either be
39 physiological or pathological. The maturation and homeostasis of the nervous cognitive abilities
40 require the participation of elements of the immune system⁶⁻⁷. Exogenous immune stimuli may also
41 have positive or negative effect on the nervous system, depending on the nature and intensity of the
42 immune response elicited^{1-4,6}. Different studies, aiming to assess the effect of immune stimuli on brain
43 function, reported i) the influence of maternal immune stimulation impairing the neurocognitive

44 performance of offspring⁸⁻⁹, ii) both beneficial and harmful effects of neonate vaccination on neuronal
45 plasticity and cognitive function in adulthood¹⁰, and iii) the damaging impact of inflammatory stimuli
46 on the cognitive function of adult mice¹¹⁻¹². Some infections may also cause neurocognitive dysfunction
47 in human and experimental models¹³⁻²⁷.

48
49 Cerebral malaria (CM), the most severe complication of falciparum malaria, can be
50 accompanied by neurocognitive sequelae, including severe motor deficit, behavioral
51 alterations and severe learning difficulties¹⁵. Long-term sequelae, responsible for child
52 ineptitude, are more common in Africa, where the prevalence of *falciparum* malaria
53 and of CM is higher²⁸. Some of these sequelae are also observed in *Plasmodium*
54 *berghei* ANKA (*PbA*) infected C57BL/6 mice, the most classical model of experimental
55 CM²⁷. In recent years, cognitive impairment, mainly related to learning and memory,
56 has also been reported in residents of endemic regions presenting non-cerebral
57 malaria (non-CM) episodes, but has not been recorded in the common murine
58 experimental models of non-CM²⁹⁻³¹.

59 In a previous work, we have unprecedentedly adapted the classical experimental
60 model of CM (*PbA*-infected C57BL/6 mice) to study neurocognitive alterations after a
61 short-term episode of non-CM³². Using this model, we evaluated here the effect of
62 immune stimuli on behavioral paradigms, such as memory and anxious phenotype,
63 during homeostasis or after a mild infection in mice.

64 Considering the data accumulated so far showing the effect of immune system on the
65 performance of neurocognitive functions, we hypothesize that some types of immune
66 stimulation may improve cognitive performance. Our data suggest an inedited
67 beneficial effect of immunization, with antigens that drive T2 immune responses, on
68 healthy mice cognitive performance and the recover of the cognitive impairment
69 associated to plasmodium infectious stress.

70

71 RESULTS

72 T2-immune stimuli improve long-term memory in healthy mice

73 The immune stimuli were categorized according to the profile of cytokine induced by
74 the specific properties of the studied immunogens. Thus, pro-inflammatory immune
75 stimuli trigger Th1 cell responses with predominance of IFN γ and TNF- α production
76 whereas polarization to an anti-inflammatory immune response profile (Th2) is
77 dependent on T-cell derived IL-4³³⁻⁴⁷. Also, levels of certain antibody isotypes may
78 indicate targeting of the immune response profile, such as IgG1 and IgG2a production
79 indicating Th2 and Th1 responses profiles, respectively⁴². Moreover, adjuvants added
80 to immune stimuli also play an important role in directing the immune response⁴³. To
81 study the effect of immune stimuli on behavioral paradigms, we employed three
82 immunization strategies according to their pro- and anti-inflammatory immune
83 response profiles. T1 strategy was used to induce a pro-inflammatory immune
84 response and T2 to elicit immune responses of type 2³³⁻⁴⁷. The Pool of antigens, for a
85 combined T1 and T2 strategy, was also used.

86

87 To address the effect of immune responses on locomotion and on long-term
88 habituation, mice were submitted to the open field task (OFT), with a training and a
89 test sessions, 24 hours apart, assessed in a well-established protocol³². Locomotion is
90 evaluated when mice access the open field arena for the first time. At the training

91 session, a high rate of locomotor activity is commonly observed. Surprisingly, Pool and
92 T1 immunized mice showed a reduced total OFT1 locomotion, when compared to non-
93 immunized mice, and T2 immunized animals showed a clear trend towards a
94 decreased locomotion (Extended data, Fig1a) Commonly, after the training session,
95 the exploratory behavior decreases, as the stress related to the novelty disappears,
96 and is significantly lower after 10 minutes of task performance^{32,48-49}. Control and all
97 immunized groups of mice presented a decreased locomotion in the test session
98 (OFT2) as compared to the training session (Extended data, Fig1a). These results
99 indicate that the immunization did not affect the long-term habituation memory
100 accessed 24 hours after training.

101

102 Mice were then subjected to the novel object recognition test (NORT) in the same Open
103 Field arena. On the training session, a similar exploratory activity of both familiar (FO1
104 or FO2) objects is expected and was observed in all groups (Control, Pool, T1 and T2)
105 of mice (Fig. 1a; Extended data, Fig. 1c), exploring them for a mean of 25 seconds (data
106 not shown). Remarkably, as we hypothesized, the groups of mice immunized with the
107 Pool and T2 strategies presented significantly higher recognition memory performance
108 in relation to the control group of non-immunized mice during the test session (Fig. 1c;
109 Extended data Fig. 1e). These data indicate, for the first time, that an immune response
110 classically categorized as anti-inflammatory (induced by T2 stimuli) may enhance long-
111 term recognition memory in healthy mice.

112

113 **Immunization of healthy mice did not influence their anxiety-like state**

114 In addition to the exploratory activity, the OFT also allows the evaluation of phenotypes
115 related to anxiety-like behavior through the dwell time or the locomotion rate in the
116 center of the open field, during the first exposition to the apparatus. Immunized mice
117 (Pool, T1 and T2) showed no difference in time (data not show) but presented a
118 significantly reduced locomotion in the center of the open field in relation to non-
119 immunized control group (Fig. 1e). However, these data may have been impacted by
120 the total reduced mobility observed in these animals (Extended data, Fig. 1a), and no
121 conclusion about anxious behavior can be scratched from these data. To address this
122 issue, we used another approach-avoidance conflict test, the classical light-dark
123 specific task, to evaluate the anxiety-like behavior. In this test, immunized mice (Pool,
124 T1 and T2) groups clearly behaved similarly to mice of the control group, remaining
125 during an equal time in the light zone (Fig.1g), implying that immunization did not
126 change the anxiety phenotype.

127

128 **T2-immune stimuli may recover the cognitive-behavioral damage caused by** 129 **non-complicated *P. berghei* ANKA infection**

130 About 92% of the world's malaria cases are due to *Plasmodium falciparum* infection, 1
131 to 2% of which progress to cerebral malaria that accounts for about 80% of deaths due
132 to malaria in the world. Thus, about 90% of malaria cases globally are caused by a
133 lethal species of *Plasmodium*, but occur without clinical complications²⁸ and may also
134 present with cognitive impairment, indicating that non-complicated malaria can impact
135 not only the children health but also their cognitive development²⁹⁻³¹.

136 The experimental model we have described uses *PbA*-infected C57BL/6 treated at day
137 4 post-infection, before appearance of any clinical sign of CM. The main advantage of
138 such a model is that it best mimics the human situation described above that

139 corresponds to the largest number of malaria cases in the world (uncomplicated
140 falciparum malaria treated timely)²⁸. Using this model, we have been able to observe
141 a long-term cognitive-behavioral impairment related to memory and anxious
142 phenotype³². With the evidence of a beneficial effect of immunization on the long-term
143 memory in healthy mice described above, we decided to evaluate the effect of the
144 same immune stimuli in mice with behavioral alterations resulting from non-CM.

145 The behavioral tests were performed 77 days after Chloroquine (CQ) treatment of
146 infected mice. *PbA*-infected and treated mice did not present total mobility reduction in
147 the training session of OFT (Extended data, Fig.1b) when compared to non-infected
148 mice. However, infected-immunized (Pool, T1 or T2) animals showed a trend towards
149 a reduction of locomotion in OFT, when compared to infected mice (Extended data,
150 Fig.1b). This trend becomes a significant reduction when locomotory activity of
151 infected-immunized mice (Pool and T2) is matched to that of healthy ones (Extended
152 data, Fig.1b).

153 As expected, there was no object preference in the NORT training session since all
154 mice explored similarly (for a mean of 25 seconds - data not show) both familiar objects
155 (Fig.1b, Extended data, Fig.1d). Control, infected and infected-immunized groups
156 (Pool and T2, but not T1) of mice presented normal behavior with a significant
157 decreased locomotion in the test session as compared to the training session of the
158 OFT (Extended data, Fig. 1b). Consistently, non-CM recovered mice presented long-
159 term recognition memory sequelae expressed by similar exploration of the FO and NO
160 in NORT. As hypothesized, this impairment disappeared after the use of the Pool and
161 T2 strategies of immunization (Fig.1d, Extended data, Fig.1f), pointing to the foreseen
162 beneficial effect of anti-inflammatory T2 immune responses reversing cognitive deficit
163 associated to malaria.

164 ***P. berghei* ANKA infection of mice induces an anxiety-like behavior that is** 165 **reverted by the T2 immunization strategy**

166 The distances travelled in the periphery and in the center of the OFT are inversely
167 related. Since the latter was decreased in *PbA* infected recovered mice (Fig.1f) and no
168 OFT1 locomotion change occurred, one can understand this effect as the expression
169 of an anxiety-like behavior (Extended data, Fig.2b). This anxiety-like behavior was also
170 detected in the light-dark task, since the infection also reduced the time spent in the
171 light zone of the apparatus. More importantly, this decrease was reversed by Pool and
172 T2 immunization (Fig.1h).

173 This is in accordance with the increased distance travelled in the periphery of the OFT
174 (data not show). This anxiety-like phenotype was, effectively, confirmed by the
175 reduction of time spent in the light zone of light-dark task. This decrease was reversed
176 by the immunization with Pool and T2 strategies (Fig.1h).

178 **Immunization procedures and non-complicated *P. berghei* ANKA malaria do** 179 **elicit specific immune responses**

180 Pool and T2 immunized mice showed increased spleen weight and total number of
181 splenocytes (Extended data, Fig. 2a,b). The specific immune responses triggered by
182 the immunogens used were evaluated and the effectiveness of the stimuli was
183 confirmed (Extended data, Fig.3a,b,c,d). We also evaluated the frequencies of B and
184 T cells, as well as the T cell activation status in the spleen, at the end of the cognitive

185 task evaluation. Mice immunized with either the Pool or the T2 strategies (Pool and T2
186 groups) presented similar patterns of modulation of different immune components
187 analyzed. We observed, in both groups, an increase in the frequency of B cells, CD4
188 and CD8 T cells with central memory phenotype and CD4 T cells with regulatory
189 function when compared to non-immunized animals (Extended data Fig.4a,b,c,d). A
190 reduction in the frequency of splenic CD8 T cells was also recorded mice immunized
191 with the T2 stimuli, when compared to the control group (Extended data, Fig.5a).
192 Besides, mice immunized with the Pool and T2 strategies presented increased serum
193 levels of IL-4 cytokine, TNF α and IFN γ (Extended data, Fig.6a,b,d).

194 Alterations in the immune response profile were also evaluated late (77 days following
195 treatment) after *PbA* infection. *PbA*-infected and treated mice showed higher frequency
196 of B cells, CD4 and CD8 T cells and increase in the frequency of CD4 and CD8 T cells
197 with naïve and central memory phenotype (Extended data, Fig.4a,b,c,e,f; Fig 5a,b).
198 The frequency of regulatory CD4 T cells, however, was similar between infected and
199 control mice (Extended data Fig.4d). Also, at the time they were immunologically
200 evaluated, infected and treated animals did not present detectable levels of serum
201 cytokines (Extended data, Fig.6a,b,c,d) and only showed an altered shade color,
202 attributable to the hemozoin pigment of the erythrocytic cycle of the *Plasmodium*
203 parasite, with no more difference in the weight and total number of splenocytes in
204 relation to the control group (Extended data, Fig.2a,b,c). It is clear, therefore, that
205 alterations of the immune system are triggered by plasmodium, even though the
206 infection is treated and contained rapidly, and that some of them can be observed
207 several weeks after parasite elimination.

208 As observed in healthy immunized animals, immunization of *PbA*-infected and treated
209 mice with Pool or T2 strategies induced splenomegaly (Extended data, Fig2a,b,c),
210 humoral immune response to the vaccine stimuli (Extended Data, Fig.3a,b,c,d) and
211 patterns of splenic B cells, CD4 and CD8 T cells and of their different function subsets
212 comparable for the two stimuli (Extended data, Fig.4a,c,d,e; Fig.5a,b). The marked
213 splenomegaly recorded after immunization could partially explain the reduced total
214 locomotion in OFT (Extended data, Fig.2a,b) and harmed conclusions on the effect of
215 immunization on anxiety-like phenotype in this behavioral task (Fig.1e,f).

216 It is important to highlight that, in general, the object exploratory pattern in NORT
217 training test was not modified in any feature considering the most rigorous aspects
218 reported in NORT protocol⁵⁰, which sustain our interpretation about the beneficial effect
219 of anti-inflammatory T2 immune responses reversing cognitive deficit associated to
220 malaria.

221 Taken together, our data point to a positive influence of immune responses induced by
222 T2 stimuli on the long-term memory in healthy mice, confirm our previous
223 demonstration of neurocognitive behavioral dysfunction after a single episode of non-
224 cerebral malaria, and indicate a recovering effect of this deficit exerted by T2
225 immunization procedures.

226

227 DISCUSSION

228 The existence of lymphocyte neuropeptide receptors⁵¹ and cytokine receptors in
229 neurons⁵² are commonplace notions that have paved the anatomical and functional
230 basis of the “classical neuroimmunology”. On the other hand, as the immune and
231 nervous systems are arrangements with cognitive functions and plastic properties, it is
232 reasonable to assume that learning in one cognitive system may influence the
233 performance of the other.

234 Different studies have shown that stimulation of the immune system may exert different
235 effects on neurocognitive function depending on the nature and balance of the immune
236 inputs^{6,51-52} and the cumulated knowledge points to the notion that, while anti-
237 inflammatory immune responses are responsible for the proper performance of the
238 brain^{51,53}, pro-inflammatory responses can impair cerebral function and neurocognitive
239 activity⁶.

240 Stimulus such as physical exercise, reading and music are mentioned cognitive
241 enhancement strategy⁵⁶⁻⁵⁹. Here, we describe, for the first time, beneficial
242 immunomodulatory effects improving cognition in healthy mice. Our findings show a
243 marked positive effect of immune stimuli specifically triggering type-2 immune
244 response by improving long-term memory of normal adult mice, as verified by the new
245 object recognition task (NORT), a robust and most used behavioral tasks for the
246 analysis of the parameter in rodents⁵⁰.

247
248 We have previously reported cognitive-behavioral impairment as late sequelae of a
249 single uncomplicated malaria episode using a MC experimental model and treating
250 animals before the appearance of any neurological sign⁶⁰. In our concept, the model
251 is illustrative and adequate for the study of the, by far, most common presentation of
252 malaria; ie: the non-cerebral *Plasmodium falciparum* malaria⁶¹. In fact, both the
253 experimental model and the human situation correspond to conditions in which we
254 have a *Plasmodium* parasite capable of causing - and a host susceptible of developing
255 - cerebral malaria that is, however, prevented by timely treatment.

256
257 As hypothesized, we were able to observe a positive effect of immune stimuli reversing
258 cognitive-behavioral impairment associated with non-complicated malaria (nCM) in the
259 prototype described above. The results show that mice with nCM, treated at D4 of *PbA*
260 infection and immunized with T2 and Pool strategies for 60 days from D11 on, did not
261 present the long-term memory sequelae - expressed by similar exploration of the FO
262 and NO in NORT - as non-immunized infected mice did. Besides, we reported anxious-
263 like behavior reversal in the light-dark task, also considered a reference tool for
264 specifically analyzing anxiety⁶²⁻⁶³, after immunization of infected and treated mice.

265
266 These results confirm our conceived idea of an effect of immune stimuli on brain
267 function and downstream consequences reflected in improvement of the cognitive-
268 behavioral performance. It is know that inflammatory stimuli may cause microglial
269 activation and increase of cytokine T1 profile such as TNF- α and IL1- β reported as evil
270 for cognitive function⁶⁴ while cytokine T2 profile are beneficial cognitive enhancers
271 such as IL-4 referred to as cytokine to remember³⁵. It has also been shown that LPS
272 can cause the basal ganglia to malfunction but the dosages applied to promote this
273 effect are higher than that used in the present study⁶⁵.

274

275 The inedited data reported here may correspond to a new paradigm and promising
276 alternative for the design of memory improvement strategies in homeostasis and
277 cognitive function impairment, including those associated to malaria and reflected as
278 poor school performance in hundreds of thousands of children in the world. In fact, the
279 relevance of maintaining an updated vaccination calendar is usually claimed for the
280 sustenance of efficient policies for prophylaxis of "immune-preventable" diseases,
281 through individual and collective protection against infections and prevention of
282 epidemics. Our data may suggest that a new thought on the importance of vaccination
283 may arise from its potential use as a strategy for boosting cognition function in health
284 and recovering cognitive dysfunctions in infectious and chronic diseases and ageing.
285 This new perceptiveness of the vaccination benefits could constitute a new weapon to
286 fight the growing anti-vaccine movement in the world.

287

288

289 REFERENCES

290

- 291 1. Jerne NK. Idiotypic networks theory and other preconceived ideas.
292 Immunological Reviews. 1984, 79: 5-24.
- 293 2. Cohen, I. The cognitive paradigm and the immunological homunculus. Immunol.
294 Tod. 1992; 13(12):490-4.
- 295 3. Cohen I. On autoimmunity. Tending Adam's Garden: evolving the cognitive
296 immune self. Acedemic Press. 2000.
- 297 4. Daniel-Ribeiro CT & Martins YC. Imagens, Micróbios e Espelhos: os sistemas
298 imune e nervoso e nossa relação com o ambiente. Ed. Fiocruz. 2017, Cap. 3:
299 pp 161-162.
- 300 5. Kivisakk P, et al. Localizing central nervous system immune surveillance:
301 meningeal antigenpresenting cells activate T cells during experimental
302 autoimmune encephalomyelitis. Ann. Neurol. 2009; 65:457–469.
- 303 6. Kipnis J, Gadini S, Derecki N. Pro-cognitive properties of T cells. Nat Rev
304 Immunol. 2012; 12 (9): 663-669.
- 305 7. Nataf S. Autoimmunity as a Driving Force of Cognitive Evolution. Front.
306 Neurosc. 2017, 11:582.
- 307 8. Schwartz JJ, Caregab M, Coburna MA, Roseb RD, Hughes HK, Paul
308 Ashwood P. Behavioral impact of maternal allergic-asthma in two genetically
309 distinct mouse strains. Bra Beh Immunit. 2017, 63: 99–107.
- 310 9. Mueller F, Polesel M, Richetto J, Meyer U, Weber-Stadlbauer U. Mouse models
311 of maternal immune activation: Mind your caging system! Bra Beh and Immunit.
312 2018, 643-660.
- 313 10. Yang J, Qi F, Zou HGJ, Yang Y, Yuan Q, Yao Z. Neonatal BCG vaccination of
314 mice improves neurogenesis and behavior in early life. Brai Resear Bulleet.
315 2016, 120: 25–33.
- 316 11. Bossu P, Cutuli D, Palladino I, Caporali P, Angelucci F, Laricchiuta GF, et. al. A
317 single intraperitoneal injection of endotoxin in rats induces long-lasting
318 modifications in behavior and brain protein levels of TNF- α and IL-18. J. of
319 Neuroimmunofl. 2012, 9:101.
- 320 12. Depino AM. Early prenatal exposure to LPS results in anxiety- and depression-
321 related behaviors in adulthood. Neuroscience. 2015, 299: 56-65.

- 322 13. Kannan G, Pletnikov MV. Toxoplasma gondii and Cognitive Deficits in
323 Schizophrenia: An Animal Model Perspective. Schizophr Bull. 2012; 38 (6):
324 1155–1161.
- 325 14. Iqbal J, Mueller U. 2007. Virus infection causes specific learning deficits in
326 honeybee foragers. Proceedings of the Royal Society B-Biological Sciences
327 274:1517–1521.
- 328 15. Odera VM, Snow RW, Newton CRJC. The burden of the neurocognitive
329 impairment associated with Plasmodium falciparum malaria in sub-Saharan
330 Africa. Am J Trop Med Hyg. 2004;71:64–70.
- 331 16. Carter JA, Lee JA, Gona JK, Murira G, Rimba K, Neville BG, et al. Severe
332 falciparum malaria and acquired childhood language disorder. Dev Med Child
333 Neurol. 2006;48:51–7.
- 334 17. Boivin MJ, Bangirana P, Byarugaba J, Opoka RO, Idro R, Jurek AM, et al.
335 Cognitive impairment after cerebral malaria in children: a prospective study.
336 Pediatrics. 2007;119:e360–6.
- 337 18. John CC, Bangirana P, Byarugaba J, Opoka RO, Idro R, Jurek AM, et al.
338 Cerebral malaria in children is associated with long-term cognitive impairment.
339 Pediatrics. 2008; 122:e92-9.
- 340 19. Kihara M; Carter J.A; Holding P.A; Khadem F.V; Scott R.C; Idro R; Fegan G.W;
341 Haan M; Neville B.G.R; Newton C.R.J.C. Malaria journal, v. 8, p. 273, 2009.
- 342 20. Holmberg D, Franzén-Rohl E, Idro R, Opoka RO, Bangirana P, Sellgren CM et
343 al. Cerebrospinal fluid kynurenine and kynurenic acid concentrations are
344 associated with coma duration and long-term neurocognitive impairment in
345 Ugandan children with cerebral malaria. Mal J. 2017, 16:303.
- 346 21. Thuilliez J, Sissoko MS, Toure OB, Kamate P, Berthelemy JC, Doumbo OK.
347 Malaria and primary education in Mali: a longitudinal study in the village of
348 Donéguébougou. Soc Sci Med. 2010;71:324–34.
- 349 22. Bangirana P, Allebeck P, Boivin MJ, John CC, Page C, Ehnvall A, et al.
350 Cognition, behaviour and academic skills after cognitive rehabilitation in Uganda
351 children surviving severe malaria: a randomised trial. BMC Neurol. 2011;11:96.
- 352 23. Fink G, Olgati A, Hawela M, Miller JM, Matafwali B. Association between early
353 childhood exposure to malaria and children's pre-school development evidence
354 from Zambia early childhood development project. Malar J. 2013;12:12.
- 355 24. Vorasan N, Pan-Ngum W, Jittamala P, Maneeboonyang W, Rukmanee P,
356 Lawpoolsri S. Long-term impact of the childhood malaria infection on school
357 performance among school children in a malaria endemic area along the Thai-
358 Myanmar border. Malar J. 2015;14:401.
- 359 25. Reverchon F, Mortaud S, Sivoyon M, Mailliet I, Laugeray A, Palomo J, et al. IL-
360 33 receptor ST2 regulates the cognitive impairments associated with
361 experimental cerebral malaria. Plos Pathog. 2017, 13(4): e1006322.
- 362 26. Desruisseaux MS, Gulinello M, Smith DN, Lee SC, Tsuji M, Weiss LM, et al.
363 Cognitive dysfunction in mice infected with Plasmodium berghei strain ANKA. J
364 Infect Dis. 2008;197:1621–7.
- 365 27. Reis PA, Comim CM, Hermani F, Silva B, Barichello T, Portella AC, et al.
366 Cognitive dysfunction is sustained after rescue therapy in experimental cerebral
367 malaria, and is reduced by additive antioxidant therapy. PloS Pathog.
368 2010;6:e1000963.
- 369 28. World Health Organization. World Malaria Report. Geneva: WHO; 2017.

- 370 29. Fernando SD, Gunawardena DM, Bandara MR, De Silva D, Carter R, Mendis
371 KN, et al. The impact of repeated malaria attacks on the school performance of
372 children. *Am J Trop Med Hyg.* 2003;69:582–8.
- 373 30. Vitor-Silva S, Reyes-Lecca RC, Pinheiro TR, Lacerda MV. Malaria is associated
374 with poor school performance in endemic area of the Brazilian Amazon. *Malar*
375 *J.* 2009;8:230.
- 376 31. Tapajós R, Castro D, Gisely Melo G, Balogun S, James M, Pessoa R, Almeida
377 A, Costa M, Pinto R, Albuquerque B, Monteiro W, Braga J, Lacerda M & Mourão
378 MP. Malaria impact on cognitive function of children in a peri-urban community
379 in the Brazilian Amazon. *Malar J.* 2019; 18:173.
- 380 32. de Sousa LP, Almeida RF, Ribeiro-Gomes FL, Carvalho LJM, Souza TM, Souza
381 DOG & Daniel-Ribeiro CT. Long-term effect of uncomplicated *Plasmodium*
382 *berghei* ANKA malaria on memory and anxiety-like behaviour in C57BL/6 mice.
383 *Parasites & Vectors.* 2018; 11:191.
- 384 33. Lavigne MV, Castro M, Mateo N, Deluchi S, Atzori C. Whole-cell *Bordetella*
385 *pertussis* vaccine component modulates the mouse immune response to an
386 unrelated soluble antigen. *Microb. and Infect.* 2002; 8:15-20.
- 387 34. Castilho SF, Chovel ML, Hernández NG, González LC, Blanco A, Hernández
388 DS, Medina MF, Tito MA, Quiñoy JLP. A *Bordetella pertussis* proteoliposome
389 induces protection in mice without affecting the immunogenicity of diphtheria
390 and tetanus toxoids in a trivalent formulation. *Clinic. and Experiment.*
391 *Vacc.Reser.* 2016; 5:175-178.
- 392 35. Goodier MR, Rodriguez-Galan A, Lusa C, Nielsen CM, Darboe A, Moldoveanu
393 AL, White MJ, Behrens R, Riley EM. Influenza Vaccination Generates Cytokine-
394 Induced Memory-like NK Cells: Impact of Human Cytomegalovirus Infection. *J.*
395 *Immunol.* 2016; 197(1):313-25.
- 396 36. Zhu W, Li S, Wang C, Yu G, Prausnitz MR, Wang BZ. Enhanced immune
397 responses conferring cross-Protection by skin Vaccination With a Tri-
398 component influenza Vaccine Using a Microneedle Patch. *Front. in Immunol.*
399 2018; 9:1705.
- 400 37. Brahimi K, Pérignon JL, Bossus M, Gras H, Tartar A, Druilhe P. Fast
401 immunopurification of small amounts of specific antibodies on peptides bound
402 to ELISA plates. *J. Immunol. Meth.* 1993; 162(1):69-75.
- 403 38. Oeuvray C, Bouharoun-Tayoun H, Grass-Masse H, Lepers JP, Ralamboranto L,
404 Tartar A, Druilhe P. A novel merozoite surface antigen of *Plasmodium falciparum*
405 (MSP-3) identified by cellular-antibody cooperative mechanism antigenicity and
406 biological activity of antibodies. *Mem. Inst. Oswaldo Cruz.* 1994; 89 Suppl 2:77-
407 80.
- 408 39. Daher LJ1, Demanga CG, Prieur E, Pérignon JL, Bouharoun-Tayoun H, Druilhe
409 P. Toward the rational design of a malaria vaccine construct using the MSP3
410 family as an example: contribution of immunogenicity studies in models. *Infect.*
411 *Immun.* 2010; 78(1):477-85.
- 412 40. Matos DCS, Marcovistz R, Cabello PH, Georgini AR, Sakauchi D, Silva LL.
413 Immunogenicity Test of Tetanus Component in Adsorbed Vaccines by Toxin
414 Binding Inhibition Test. *Mem Inst Oswaldo Cruz.* 2002, 97(6): 909-913.
- 415 41. Lima MCR, Prouvost-Danon A, Patricia MR, Chagas MS, Calheiros AS,
416 Cordeiro RSB. Studies on the mechanisms involved in antigen-evoked pleural.
417 *J of Leuk Biol.* 1997, 61.

42. Comoy EE, Capron A, Thyphronitis G. In vivo induction of type 1 and 2 immune responses against protein antigens. *Int. Immunol.* 1997; 9(4):523-31.
43. Terhune TD, Deth RC. Aluminum Adjuvant-Containing Vaccines in the Context of the Hygiene Hypothesis: A Risk Factor for Eosinophilia and Allergy in a Genetically Susceptible Subpopulation?. *Internat. J. of Environment. Researc. and Publ. Health.* 2018; 15:901.
44. Bosmann M, Russkampa NF, Warda PA. Fingerprinting of the TLR4-induced acute inflammatory response. *Exp. Mol. Pathol.* 2012; 93(3): 319–323.
45. Kozyreva VS, Subbotovskaia AI, Shilova AN, Karpenko AA. Immunological aspects of formation of restenoses after endothelial lesions. *Angiol Sosud Khir.* 2014; 20(1):21-6.
46. Couch Y, Trofimov A, Markova3 N, Nikolenko V, Steinbusch HW, Chekhonin V, Schroeter C, Lesch KP, Anthony DC, Strekalova T. Low-dose lipopolysaccharide (LPS) inhibits aggressive and augments depressive behaviours in a chronic mild stress model in mice. *J. of Neuroinflamm.* 2016; 13:108.
47. Fontana MF, Baccarella A, Kellar D, Oniskey TK, Terinate P, Rosenberg SD et. al. Myeloid expression of the AP-1 transcription factor JUNB modulates outcomes of type 1 and type 2 parasitic infections. 2015, 37(9): 470–478.
48. Almeida RF, Ganzella M, Machado DG, Loureiro SO, Leffa D, Quiconzes Santos A, et al. Olfactory bulbectomy in mice triggers transient and longlasting behavioural impairments and biochemical hippocampal disturbances. *Prog Neuropsychopharmacol Biol Psychiatry.* 2017;76:1-11.
49. Figueiredo CP, Clarke JR, Ledo JH, Ribeiro FC, Costa CV, Melo HM, et al. Memantine rescues transient cognitive impairment caused by highmolecular-weight a β oligomers but not the persistent impairment induced by low-molecular-weight oligomers. *J Neurosci.* 2013;33:9626–34.
50. Leger M, Quiedeville A, Bouet V, Haelewyn B, Boulouard M, Schumann-Bard P, Freret T. Object recognition test in mice. *Nat Protoc.* 2013; 8(12):2531-7.
51. Gandani SP, Cronk JC, Norris GT, Kipnis J. Interleukin-4: A Cytokine to Remember. *J. Immunol.* 2012, 189(9): 4213–4219.
52. Brombacher TM, De Gouveia KS, Cruywagen L, Makena N, Booley F, Tamgue O, et al. *Nippostrongylus brasiliensis* infection leads to impaired reference memory and myeloid cell interference. *Nature.* 2018; 8:2958.
53. Brynskikh A, Warren T, Zhu Z, Kipnis J. Adaptive immunity affects learning behavior in mice. *Bran, Behav and Immun.* 2008; 22: 861-869.
54. Zuo Z, Qi F, Yang J, Wang X, YaruWen Y, Yuan Q. Immunization with *Bacillus Calmette-Guérin* (BCG) alleviates neuroinflammation and cognitive deficits in APP / PS1 mice via the recruitment of inflammation-resolving monocytes to the brain. *Neurob of Disea.* 2017, 101: 27–39.
55. Gu CJ, Borjabad A, Hadas E, Kelschenbach J, Kim BH, Chao W et. al. EcoHIV infection of mice establishes latent viral reservoirs in T cells and active viral reservoirs in macrophages that are sufficient for induction of neurocognitive impairment. *Plos Pathog.* 2018; 14(6):e1007061.
56. Voss MW, Weng TB, Narayana-Kumanan K, Cole RC, et. al. Acute Exercise Effects Predict Training Change in Cognition and Connectivity. *Med Sci Sports Exerc.* 2019.

- 465 57. Moreau D, Chou E. The Acute Effect of High-Intensity Exercise on Executive
466 Function: A Meta-Analysis. *Perspect Psychol Sci.* 2019;14(5): 734-764.
- 467 58. Ji Z, Feng T, Mei L, Li A and Zhang C. Influence of acute combined physical and
468 cognitive exercise on cognitive function: an NIRS study. *PeerJ.* 2018; 12.
- 469 59. Loprinzi PD, Harris F, McRaney K, Chism M, Deming R, Jones T, Zou L, Tan
470 M. Effects of Acute Exercise and Learning Strategy Implementation on Memory
471 Function. *Medicina (Kaunas).* 2019; 5: 55 (9).
- 472 60. Potter S, Chan-Ling T, Ball HJ, Mansour H, Mitchell A, Maluish L, et al. Perforin
473 mediated apoptosis of cerebral microvascular endothelial cells during
474 experimental cerebral malaria. *Int J Parasitol.* 2006;36:485–96.
- 475 61. World Malaria Report. 2018. World Health Organization.
- 476 62. Almeida RF, Comasseto DD, Ramos DB, Hansel G, Zimmer ER, Loureiro SO,
477 et al. Guanosine anxiolytic-like effect involves adenosinergic and glutamatergic
478 neurotransmitter systems. *Mol Neurobiol.* 2016;54:423-36.
- 479 63. Griebel G, Holmes A. 50 years of hurdles and hope in anxiolytic drug discovery.
480 *Nat Rev Drug Discov.* 2013; 12(9):667-87.
- 481 64. Hoogland ICM, Houbolt C, Westerloo DJV, Gool WAV and Beek D. Systemic
482 inflammation and microglial. *Journal of Neuroinflammation.* 2015; 12:114.
- 483 65. Ramsey CP, Tansey MG. A survey from 2012 of evidence for the role of
484 neuroinflammation in neurotoxin animal models of Parkinson's disease and
485 potential molecular targets. *Ex. Neurol.* 2014; 256:126-32.

486

487

488 **ACKNOWLEDGEMENTS**

489 LPS is grateful to the *Programa de Pós-Graduação em Biologia Parasitária* of the
490 *Instituto Oswaldo Cruz (IOC) of Fundação Oswaldo Cruz (Fiocruz)* for the Doctoral
491 fellowship. The authors are grateful to the *Laboratório de Inflamação* (Dr. Marco
492 Aurélio Martins and Dr. Tatiana Ferreira), *Laboratório de Pesquisa em Malária* (Luana
493 santos Thalita Ferraz), *Laboratório de Pesquisa sobre o Timo* of the *IOC-Fiocruz* (Dr
494 Daniella Mendes Arêas and Dr Dyna Raposo) of *IOC*; *Biomanguinhos* (Dr. Maria de
495 Lourdes de Sousa Maia, Alessandro Fonseca, Camilla Bayma, and Denise Cristina
496 Matos) and *Farmanguinhos* (Dr. Márcia Coronha Ramos Lima and Dr. Andréa Luca)
497 of *Fiocruz and Instituto Butantan* (Dr. Jorge Kalil and Dr. Paulo Lee Ho and Aline
498 Abrantes) and *Vac4all* (Dr. Pierre Duiilhe) for reagent supply and study of the immune
499 response to vaccines.

500

501 **FUNDING**

502 This work is part of LPS's PhD research supported by CAPES (Brazil) and by Faperj
503 (RJ, Brazil) fellowships. GLW, DOS and CTDR are supported by CNPq, Brazil, through
504 a Productivity Research Fellowship and GLW and CTDR are "*Cientistas do Nosso*
505 *Estado*" recognized by the Faperj. The *Laboratório de Pesquisa em Malária, IOC,*
506 *Fiocruz* and the *Departamento de Bioquímica* of the *Universidade Federal do Rio*
507 *Grande do Sul* are National Institutes of Science & Technology (INCT) associated
508 Laboratories.

509

510

511 **AUTHOR CONTRIBUTIONS**

512 LPS was responsible for the realization of all experiments (including infection and
513 treatment; immune stimulation, and conduction, observation and data
514 collection/systematisation of cognitive tests and immune response analyses in mice),
515 helped in the analysis and interpretation of tests and drafted the manuscript. FLRG
516 followed all the stages of the experiment, realization of experiments, discussed the
517 protocols and the project, was in charge of the analysis and discussion of immune
518 response data and helped in drafting the manuscript. RFA and TMS helped in
519 systematization of data concerning behavioral tests and analyzed and interpreted the
520 cognitive data. GW proposed the statistical analyzes of the data and was responsible
521 for it. DOS discussed the project since its conception and helped in designing the
522 experiments. CTDR is responsible for conception and design of the study, and helped
523 in data analysis, interpretation and drafting and finalizing the manuscript together with
524 LPSV and FLRG. All authors read, reviewed and approved the final manuscript.

525

526

527 **COMPETING INTERESTS**

528 The authors declare that they have no competing interests.

529

530 METHODS

531

532 **Mice and Parasite.** The “Instituto de Ciência e Tecnologia em Biomodelos” of the
533 “Fundação Oswaldo Cruz” (ICTB- Fiocruz, Brazil) granted seven week-old C57BL/6
534 female mice weighing 20-25 g. Mice were conditioned housed in racks with an air
535 filtration system in a room maintained at 25°C and light/dark cycles of 12 hours in cages
536 containing five animals with free acquisition to food and water. All procedures were
537 carried out in accordance with animal welfare approved by the Ethical Committee on
538 the Use of Laboratory Animals of “Instituto Oswaldo Cruz” under CEUA-IOC: L-
539 010/2015 concession. *Plasmodium berghei* ANKA (*PbA*) infections were carried out
540 using a stable transfected strain of *PbA* expressing a green fluorescent protein (*PbA*-
541 GFP) generated as described previously¹.

542

543 **Infection and treatment of experimental groups.** C57BL/6 mice were infected
544 intraperitoneally (ip) with 150 µl of *PbA*-infected red blood cells, duly cryopreserved
545 and thawed, being called “mice-passage.” Five days after infection, the total blood was
546 collected, adjusted to 1 x10⁶ parasitized erythrocytes in 100 µl of PBS and injected in
547 the peritoneum of C57BL/6 mice from the experimental groups. Parasitemia was
548 monitored by flow cytometry, based on the percentage of GFP⁺ erythrocytes. In this
549 experimental model, the evolution to and establishment of cerebral malaria (CM) occur
550 between the fifth and sixth day of infection². In this study, mice were treated on the
551 fourth day of infection (mean parasitaemia 2.5%) with 25 mg/kg of chloroquine (CQ)
552 by gavage for seven days³, before any clinical signs of CM. All groups were similarly
553 manipulated on procedures. Experiments carried out with groups of uninfected mice
554 treated with CQ or not (control group received PBS) have previously shown, that the
555 CQ treatment did not influence the performance in behavioral tasks and anxiety
556 phenotype⁴.

557

558 **Experimental Description.** C57BL/6 mice were divided into groups of *PbA* infected
559 and Control animals (no infected) and both were treated with chloroquine (CQ) for
560 seven days from the fourth day of infection. Thirteen days after treatment, mice from
561 respective groups were subdivided into Non-Immunized and Immunized groups (Fig.
562 1). The following vaccines and antigens were used for immunization: Diphtheria and
563 Tetanus toxoids (dT) vaccine for adults, Influenza vaccine, *Plasmodium falciparum*
564 Merozoite Surface Protein 3 (pfMSP-3), White chicken egg ovalbumin (OVA) and
565 Lipopolysaccharide of *Escherichia coli* (ecLPS). Three different immunization
566 strategies were performed: a combination of all antigens and vaccines described
567 above (from here now, called Pool); a combination of antigens and vaccines (Influenza
568 vaccine and ecLPS) that trigger, preferentially, a type 1 pattern of immune response
569 (from here now, denominated T1); and a combination of antigens and vaccines (dT
570 vaccine, pfMSP-3 and OVA) that trigger, preferentially, a type 2 pattern of immune
571 response (from here now, called T2). The groups of mice were denominated: Control
572 (Non-infected/Non-Immunized); Pool, T1 and T2 (Non-infected/Immunized Pool, T1 or
573 T2 of the immunization strategy); Inf (Infected/Non-immunized); and Inf-Pool, T1 or T2
574 (Infected/Immunized Pool, T1 or T2 of the immunogens inoculation strategy).
575 Subsequently, mice behavioral performance was assessed by Open Field Test (OFT),
576 Novel Object Recognition Test (NORT) and Light-Dark (L/D) (Fig. 2). About 300 mice
577 were used for these experimental strategies in five consecutive sessions.

578 **Immune system stimuli.** The immune stimulus was initiated thirteen days after the
579 end of CQ treatment, being performed in the course of the following sixty days (Fig. 2).
580 Antigens and/or vaccines were administered by different routes, in different regions of
581 the animals's body (Table 1). The doses administrated were defined based on dose-
582 response protocols available in the literature capable of stimulating the murine immune
583 system without imparting risk of death to mice immunized⁵⁻¹².

584

585 **Immunization with Plasmodium falciparum Merozoite Surface Protein 3 (pfMSP-
586 3).** The mice were challenged with 10 µg of pfMSP-3 recombinant (in collaboration with
587 Clinical Trials of Malaria Vaccines (Vac4All Initiative), Paris, France) adsorbed on 70%
588 adjuvant solution MONTANIDE™ ISA 50 V2 W / O (SEPPIC. Air Liquide - Healthcare),
589 in 100 µl of PBS. Three subcutaneous injection were performed at the tail region with
590 a twenty-day interval between immunizations⁹⁻¹⁰ (Fig. 2, Table 1).

591

592 **Immunization with Tetanus- Diphtheria and Influenza Vaccines.** The vaccines
593 used in this study were: bacterial double [(Tetanus-Diphtheria (dT): Biological E
594 Limited - BE, Telangana - India, Lot. 34005815. In collaboration with the Division of
595 Health Surveillance - CAP 3.1 of the "Fundação Oswaldo Cruz", Rio de Janeiro, Brazil]
596 and Trivalent Influenza (granted by the Technological Development and Production
597 Division of "Instituto Butantan, São Paulo, Brazil, Lot. 160034).

598

599 Mice received 100 µl (1/5 of the human dose) of dT and Influenza vaccines by
600 subcutaneous (dorsal region) and intramuscular (left quadriceps region), routes
601 respectively (Table 1). Three inoculations with a twenty-day interval between
602 immunizations were performed⁵⁻⁶ (Figure 2).

603

604 **Immunization with Ovalbumin (allergen).** Mice received 50 µg of white chicken egg
605 ovalbumin (SIGMA-ALDERICH, Cod. A5503-50g) adsorbed onto aluminum hydroxide
606 [Al (OH) 3] in a final volume of 200 µl per animal in three inoculations. The first
607 inoculation was performed at the dorsal region by subcutaneous injection and the
608 following (second and third inoculation) by ip route (Table 1) with seven days between
609 them¹¹ (Fig. 2).

610

611 **Immunization with Lipopolysaccharide from *Escherichia coli* (ecLPS).** Mice were
612 challenged with 0.1 mg/kg of ecLPS O111: B4 (SIGMA-ALDERICH, L2630-10MG, Lot
613 025M4040V12140701) diluted in phosphate-buffered saline (PBS). Two ip inoculations
614 were performed (Table 1) with a range of ten days between immunizations¹² (Fig. 2).

615

616 **Evaluation of the immunization efficacy.** Mice were randomly selected and
617 sacrificed for withdrawal of whole blood via cardiac puncture following stimulation of
618 the immune system (twenty days after the last immunization with pfMSP-3 and dT and
619 Influenza vaccines; six days after the last inoculation of Ovalbumin and two days after
620 the last dose of ecLPS), serum samples were preserved at -70 ° C. Total IgG against
621 pfMSP-3, Tetanus-Diphtheria toxoids (dT) and Influenza vaccine; the Th1, Th2 and
622 Th17 cytokine profile; lymphocyte subpopulations spleen; and intradermal test for the
623 response against Ovalbumin were evaluated.

624

625 The antibody response against pfMSP-3 recombinant and Influenza vaccine were
626 determinate by conventional Enzyme-Liked immunosorbent Assay – ELISA⁹⁻¹⁰, and

627 the antibody response against dT vaccine was determined by Toxin Binding Inhibition
628 – ToBI¹³.

629

630 **Evaluation of the immune response triggered by immunization.** Cytokine
631 production triggered by the Pool, T1 and T2 stimuli was evaluated in the serum of the
632 different mice groups. Cytokine profile was performed by Cytometric Bead Array
633 Th1/Th2/Th17 (CBA - BD Biosciences (cat# 560484). The data were collected and
634 analyzed using FACS CANTO flow cytometer (BD Biosciences) and FACScomp (BD),
635 respectively. Spleens from the animals of all groups were removed and homogenized
636 with a syringe plunger above 70- μ m strainer, and red blood cells were eliminated by
637 using ACK lysing buffer (Sigma). The cell suspension was counted and
638 immunolabeled. For staining, cells were incubated with anti-Fc III/II (CD16/32)
639 receptor Ab (2.4G2), followed by surface staining with various combination of the
640 following antibodies for 30 min at 4°C in the dark: anti-CD8 (PE-Cy7, 53-6.7 clone, BD
641 Pharmingen), anti-CD3 (PerCPCy 5.5, 145-2c11 clone, BD Pharmingen), anti-CD4
642 (APC-H7, GK1.5 clone, BD Pharmingen), anti-B220 (APC, RA3-6B2 clone, BD
643 Pharmingen), anti-CD62L (BB515, MEL14 clone, BD Horizon), APC anti-CD44 (APC,
644 IM7 clone, BD Pharmingen) and Foxp3 (Alexa Flour, 647, R16715, BD Pharmingen).
645 Acquisition and data analyze by flow cytometry using BD FACSCanto™ and FlowJo
646 ®.

647

648 **Behavioral analysis.** Mice behavioral performance was assessed according to the
649 experimental schedule presented in Fig. 2. To note, mice was submitted to different
650 behavioral paradigms to evaluate exploratory and locomotor activity, cognitive abilities,
651 and parameters involved in anxiety-like behavioral at days twenty one, seven and three
652 days after *pfMSP-3*, Tetanus-Diphtheria and Influenza vaccine; Ovalbumin; LPS
653 inoculation, respectively, and seventy seven days after CQ treatment. The same co-
654 hort of mice were evaluated on OFT, NORT, Y-maze and L/D, respectively (Fig. 2). All
655 experiments were performed with incandescent light source of 200 lux of intensity in
656 the evening period. Animals were acclimatized in the experimental room at least for 2
657 hours before the experimental sessions. Behavioral performance of mice was recorded
658 by AnyMaze® software (Stoelting Co., Wood Dale, IL, USA) that captures the videos
659 and interpret exclusively the mice open field performance and only the locomotor
660 activity in the novel object recognition training and test sessions. A trained blind-to-
661 treatment researcher evaluate others behavioral parameters of each mouse
662 individually by video analysis. In all behavioral tests mice were individually placed on
663 the apparatus and monitored by a video camera (positioned above and at 90 ° of the
664 equipment) connected to a monitor to obtain images and data analyze. The apparatus
665 were properly cleaned with 70% alcohol and dried after each test.

666

667 **Open Field Task (OFT).** To address the effect of immune responses on locomotion
668 and on long-term habituation, mice were submitted to the open field task (OFT) with a
669 training and a test session 24 hours apart, as described elsewhere⁴. In each OFT
670 session [training (OFT1) and test, (OFT2)] mice was individually submitted to freely
671 explore a gray acrylic square box in (50 × 50 × 50 cm, length × width × height) for 10
672 minutes. In the training session it was evaluated the short-term habituation to novelty
673 by decreasing the distance travelled during the 1st to 3rd minute, since mice typically
674 exhibit less exploratory behavior during the first few minutes of testing in a familiar
675 open field arena; the locomotor activity (the distance travelled during the last 6 minutes

676 of the test); and anxiety-like behavior by the time and distance travelled in the center
677 zone. In the test session (OFT2), we evaluate the first 3rd and the last 7th minutes total
678 distance travelled. Finally, it was analyzed the long-term habituation to novelty,
679 characterized by a significant decrease in the total distance travelled comparing the
680 first 3 minutes of the OFT test (OFT2) with the OFT training (OFT1) sessions.

681

682 **Novel Object Recognition Task (NORT).**

683 To evaluate the recognition memory, the NORT was carried out in the same OFT
684 apparatus, 24 hours after the OFT2 session⁴. NORT starts with a training session, in
685 which mice are exposed to two familiar objects: FO1 and FO2. On the training session,
686 a similar exploratory activity (of approximately 20 seconds) of mice for both familiar
687 objects familiar, is expected¹⁵. The test session is performed 24 hours later. Mice are
688 exposed to a New Object (NO) and to one of the previously exposed Familiar Objects
689 (FO1 or FO2). NORT is based on the tendency of mice to differentiate a novel object
690 (NO) from a familiar object (FO), thus exploring more the NO in detriment of the FO^{4,15}.

691

692 Animals were placed in the periphery of the apparatus with the FO and allowed to
693 explore them 10 minutes. To the NORT test session, 24 h after the training session,
694 the animals were placed back in the arena with one of the FO and the NO to measure
695 the long-term recognition memory. The time spent exploring the objects were again
696 evaluated for 10 min by a trained blind-to-treatment observer, and an exploration was
697 only considered when the animal's nose or mouth was in contact with the objects.
698 During both the training and the test phase, objects are located in opposite and
699 symmetrical corners of the arena. In the training session both objects are novelty and
700 time explored on both should be similar. Differently, a successful test session is
701 indicated by a longer time spent on NO. The time exploration was expressed as
702 percentage of time exploring each object. Animals that recognized the NO as such
703 explored it for more than 50% of the total time.

704

705 **Light/Dark Task.** The light / dark task was performed as described by Almeida and
706 collaborators¹⁶ with minor modification to measure anxiety behavior-like phenotype¹⁷.
707 The apparatus consist in a rectangular box (50 x 30 x 30 cm, height x length x width)
708 in acrylic with two different sides (colored white and black), separated by a wall (5x5cm)
709 with an opening at the level of the base of the apparatus joined both sides of the
710 apparatus. A white 100W lamp, placed 60cm above the center of the apparatus,
711 illuminated the white side of the apparatus, while the black side was kept closed without
712 illumination. The mice were individually placed in the light compartment for free
713 exploration of the apparatus for 5 minutes. The following behavioral parameters were
714 analyzed: the time spent in the light compartment and the number of transitions
715 between the compartments (light and dark).

716

717 **Statistical analysis.** All statistical analyses were performed using a statistical software
718 package (Prism 5.0, GraphPad). The data were extracted from the AnyMaze®
719 software. To analyze OFT and Light / Dark task were used absolute data. The time in
720 each object in NORT was transformed into a percentage, from which the delta was
721 extracted based on the subtraction: OF1 - OF2 (training session) and NO - FO (test
722 session). The two-way ANOVA with Bonferroni correct were used to analyze OFT. The
723 Student t-test with Mann-Whitney correction were used for to analyze the groups in

724 NORT, light-dark task and immune response. Data are presented as mean \pm standard
725 error. $P < 0.05$ was considered statistically significant.

726

727

728 References

729

730 1. Franke-Fayard B, Trueman H, Ramesar J, Mendoza J, Van der Keur M, Van

731 der Linden R, et al. A *Plasmodium berghei* reference line that constitutively

732 expresses GFP at a high level throughout the complete life cycle. *Mol Biochem*

733 *Parasitol.* 2004;137:23–33.

734 2. Potter S, Chan-Ling T, Ball HJ, Mansour H, Mitchell A, Maluish L, et al. Perforin

735 mediated apoptosis of cerebral microvascular endothelial cells during

736 experimental cerebral malaria. *Int J Parasitol.* 2006;36:485–96.

737 3. Reis PA, Comim CM, Hermani F, Silva B, Barichello T, Portella AC, et al.

738 Cognitive dysfunction is sustained after rescue therapy in experimental cerebral

739 malaria, and is reduced by additive antioxidant therapy. *PLoS Pathog.*

740 2010;6:e1000963.

741 4. de Sousa LP, Almeida RF, Ribeiro-Gomes FL, Carvalho LJM, Souza TM, Souza

742 DOG & Daniel-Ribeiro CT. Long-term effect of uncomplicated *Plasmodium*

743 *berghei* ANKA malaria on memory and anxiety-like behaviour in C57BL/6 mice.

744 *Parasites & Vectors.* 2018; 11:191.

745 5. Lavigne MV, Castro M, Mateo N, Deluchi S, Atzori C. Whole-cell *Bordetella*

746 *pertussis* vaccine component modulates the mouse immune response to an

747 unrelated soluble antigen. *Microb. and Infect.* 2002; 8:815-820.

748 6. Castilho SF, Chovel ML, Hernández NG, González LC, Blanco A, Hernández

749 DS, Medina MF, Tito MA, Quiñoy JLP. A *Bordetella pertussis* proteoliposome

750 induces protection in mice without affecting the immunogenicity of diphtheria

751 and tetanus toxoids in a trivalent formulation. *Clinic. and Experiment.*

752 *Vacc.Reser.* 2016; 5:175-178.

753 7. Goodier MR, Rodriguez-Galan A, Lusa C, Nielsen CM, Darboe A, Moldoveanu

754 AL, White MJ, Behrens R, Riley EM. Influenza Vaccination Generates Cytokine-

755 Induced Memory-like NK Cells: Impact of Human Cytomegalovirus Infection. *J.*

756 *Immunol.* 2016; 197(1):313-25.

757 8. Zhu W, Li S, Wang C, Yu G, Prausnitz MR, Wang BZ. Enhanced immune

758 responses conferring cross-Protection by skin Vaccination With a Tri-

759 component influenza Vaccine Using a Microneedle Patch. *Front. in Immunol.*

760 2018; 9:1705.

761 9. Oeuvray C, Bouharoun-Tayoun H, Grass-Masse H, Lepers JP, Ralamboranto L,

762 Tartar A, Druilhe P. A novel merozoite surface antigen of *Plasmodium falciparum*

763 (MSP-3) identified by cellular-antibody cooperative mechanism antigenicity and

764 biological activity of antibodies. *Mem. Inst. Oswaldo Cruz.* 1994; 89 Suppl 2:77-

765 80.

766 10. Daher LJ1, Demanga CG, Prieur E, Pérignon JL, Bouharoun-Tayoun H, Druilhe

767 P. Toward the rational design of a malaria vaccine construct using the MSP3

768 family as an example: contribution of immunogenicity studies in models. *Infect.*

769 *Immun.* 2010; 78(1):477-85.

770 11. Lima MCR, Prouvost-Danon A, Patricia MR, Chagas MS, Calheiros AS,

771 Cordeiro RSB. Studies on the mechanisms involved in antigen-evoked pleural.

772 *J of Leuk Biol.* 1997, 61.

- 773 12. Couch Y, Trofimov A, Markova³ N, Nikolenko V, Steinbusch HW, Chekhonin V,
774 Schroeter C, Lesch KP, Anthony DC, Strekalova T. Low-dose
775 lipopolysaccharide (LPS) inhibits aggressive and augments depressive
776 behaviours in a chronic mild stress model in mice. *J. of Neuroinflamm.* 2016;
777 13:108.
- 778 13. Matos DCS, Marcovistz R, Cabello PH, Georgini AR, Sakauchi D, Silva LL.
779 Immunogenicity Test of Tetanus Component in Adsorbed Vaccines by Toxin
780 Binding Inhibition Test. *Mem Inst Oswaldo Cruz.* 2002, 97(6): 909-913.
- 781 14. Almeida RF, Ganzella M, Machado DG, Loureiro SO, Leffa D, Quiconzes
782 Santos A, et al. Olfactory bulbectomy in mice triggers transient and longlasting
783 behavioural impairments and biochemical hippocampal disturbances. *Prog*
784 *Neuropsychopharmacol Biol Psychiatry.* 2017;76:1-11.
- 785 15. Leger M, Quiedeville A, Bouet V, Haelewyn B, Boulouard M, Schumann-Bard
786 P, Freret T. Object recognition test in mice. *Nat Protoc.* 2013; 8(12):2531-7.
- 787 16. Almeida RF, Comasseto DD, Ramos DB, Hansel G, Zimmer ER, Loureiro SO,
788 et al. Guanosine anxiolytic-like effect involves adenosinergic and glutamatergic
789 neurotransmitter systems. *Mol Neurobiol.* 2016;54:423-36.
- 790 17. Griebel G, Holmes A. 50 years of hurdles and hope in anxiolytic drug
791 discovery. *Nat Rev Drug Discov.* 2013; 12(9):667-87.

792

793 LEGENDS FOR FIGURES AND TABLE

794 **Fig. 1. Behavioral analysis of healthy and *PbA*-infected mice.** In the New Object
795 Recognition Task (NORT), mice explored similarly the familiar objects in the training
796 session: **a)** in healthy mice and **b)** in infected mice. In the test session, **c)** control
797 (non-infected non-immunized mice) group showed increased new object
798 exploration, as expected. Mice immunized with the Pool and T2 Ag showed
799 increased new object exploration as compared to the Control and the T1 groups and
800 **d)** infected mice showed decreased new object exploration in relation to the mice of
801 the Control and Infected-Immunized groups. In the OFT1, **e)** all groups of healthy
802 immunized mice walked less in the center of the arena when compared to the control
803 group mice and **f)**, the infected mice showed a decrease in the distance travelled in
804 the center of the OFT1, as compared to the non-infected mice group. No difference
805 was observed in the light / dark task between **g)** healthy mice groups. In contrast,
806 **h)** *PbA*-infected mice groups presented anxiety-like behavioral which was
807 attenuated after immunization with the Pool and T2 immune strategies. Healthy mice
808 groups (Control, n = 6; Pool, n = 8; T1, n = 8 and Control, n = 10; Pool, n = 10; T2,
809 n = 10) and infected mice groups (Control, n = 6; Inf, n = 8; Inf-Pool, n = 6; Inf-T1, n
810 = 6 and Control, n = 25; Inf, n = 17; Inf-Pool, n = 20; Inf-T2, n = 18). Data are mean
811 and s.e.m. *** $P < 0.001$; ** $P < 0.01$; * $P < 0.05$; Unpaired t-test without and with
812 Mann-Whitney test was used. For the NORT and OFT analysis, data are
813 representative of five (Control, Pool and Inf-Pool groups), one (T1, T2 and Inf-T1
814 groups) and two (Inf-T2 group) independent experiments; and for the light-dark
815 analysis, data are representative of four (Control, Pool and Inf-Pool groups), one
816 (T1, T2 and Inf-T1 groups) and two (Inf-T2 group) independent experiments.
817

818 **Extended data, Fig. 1. Behavioral analysis of healthy and infected mice.** In the
819 open field task (OFT), all groups showed a reduction in the distance travelled in the
820 test session (OF2) when compared to the training session (OF1), **a)** healthy mice
821 groups (Control, n = 6; Pool, n = 8; T1, n = 8 and Control, n = 10; Pool, n = 10; T2)
822 and **b)** infected mice groups (Control, n = 6; Inf, n = 8; Inf-Pool, n = 6; Inf-T1, n = 6
823 and Control, n = 25; Inf, n = 17; Inf-Pool, n = 20; Inf-T2, n = 18). The (Pool and T1)
824 immunized mice groups **a)** walked less on OFT1 when compared to non-immunized
825 mice and the T2 immunized group showed a tendency ($P = 0.0524$) towards a
826 decrease in the distance travelled. The same was observed in the infected and Pool
827 and T2 immunized mice groups, **b)** but only when compared to non-infected / non-
828 immunized mice group. Data are representative of five (Pool and Inf-Pool groups),
829 one (T1, T2 and Inf-T1 groups) and two (Inf-T2 group) independent experiments. In
830 the new object recognition task (NORT), all groups of mice explored similarly the
831 familiar objects in the training session: **c)** healthy mice groups and **d)** Infected mice
832 group. **e)** The control group (non-infected non-immunized mice) showed and
833 increased new object exploration, as expected, and the Pool group showed a still
834 increased new object exploration as compared to the Control group. The infected
835 mice **f)** showed a decreased exploration of the new object, when compared to the
836 control group mice; differently from the infected and Pool Immunized mice. Healthy
837 mice group (Control, n = 22 ; Pool, n = 21) and infected mice group (Control, n = 22;
838 Inf, n = 20; Inf-Pool, n = 21). Data are representative of two independent
839 experiments for all groups. Data are mean and s.e.m. *** $P < 0.001$; ** $P < 0.01$;
840 * $P < 0.05$; Two-way ANOVA (a, b) and Unpaired t-test (c, d, e, f) was used.
841

842 **Extended data, Fig. 2. Spleen weight and size, and total number of spleen**
843 **cells.** Immunized mice showed increases in the **a)** spleen weight and **b)** total
844 number of splenocytes. **c)** Representative photograph of all studied groups of mice.
845 Groups of infected mice showed a dark color attributed to hemozoin, even two and
846 a half months after infection. All groups of immunized mice showed increased spleen
847 sizes. Samples were collected after the behavioral evaluation. Five mice per group
848 were analyzed. Data are mean and s.e.m. ** $P < 0.01$; * $P < 0.05$; Unpaired t-test with
849 Mann-Whitney test was used.
850

851 **Extended data, Fig. 3. Immune response against dT and influenza vaccines;**
852 **pfMSP-3 and OVA.** Specific immune responses were triggered by : **a)** dT (n = 7
853 mice per group); **b)** Influenza vaccine (Control, n = 6; Pool, n = 6; T1, n = 3; Inf, n =
854 6; Inf-Pool, n = 6; Inf-T1, n = 3); **c)** pfMSP-3 (n = 5 mice per group) and **e)** OVA
855 (Control, Pool and T2, n = 5 mice per group; Inf, Inf-Pool and Inf-T2, n = 4 mice per
856 group), confirming the effectiveness of the immune stimuli. Mice were randomly
857 chosen from the experiments, according to the type 1 and 2 immunization strategies,
858 for the analysis of the immune responses. Samples were collected before the
859 behavioral evaluation for analysis of responses against dT and influenza vaccines
860 and were collected after behavior tests for the study of other parameters. Data are
861 mean and s.e.m. ** $P < 0.01$; * $P < 0.05$; Unpaired t-test with Mann-Whitney test was
862 used.
863

864 **Extended data, Fig. 4. Flow cytometry analysis of B and T cell subpopulations**
865 **in the spleen.** Healthy or infected and treated mice were immunized, or not, with
866 Pool or T2 strategy and the populations of interest analyzed at the end of the
867 cognitive behavioral tasks. **a)** representative gating strategy to identify the
868 populations of B cells (B220+), CD4 T cells (CD3+CD4+), CD8 T cells (CD3+CD8+)
869 and T regulatory cells (CD3+CD4+CD25+Foxp3+); frequency of **b)** B cells; **c)** CD4
870 T cells and **d)** CD8 T cells per spleen and **e)** frequency of Treg cells among the CD4
871 T cells. Five mice were randomly chosen per group, after behavior tests, for the
872 analysis. Data are mean and s.e.m. ****P** < 0.01; ***P** < 0.05; Unpaired t-test with
873 Mann-Whitney test was used.
874

875 **Extended data, Fig. 5. Analysis of different subsets of splenic CD4 and CD8 T**
876 **cells.** Healthy or infected and treated mice were immunized, or not, with Pool or T2
877 strategy and populations of interest analyzed at the end of the cognitive behavioral
878 tasks: **a)** representative gating strategy to identify the Naïve (gate: 1; CD44⁻
879 CD64L⁺); Effector/Effector Memory (gate: 2; CD44⁺CD64L⁻) and Central Memory
880 (gate: 3; CD44⁺CD64L⁻) subpopulations of CD4 and CD8 T cells; frequency of **b)**
881 Naïve; **c)** Effector/Effector Memory and **d)** Central Memory subsets of CD4 T cells;
882 frequency of **e)** Naïve; **f)** Effector/Effector Memory and **g)** Central Memory subsets
883 of CD8 T cells. Five mice were randomly chosen per group, after behavior tests, for
884 the analysis. Data are mean and s.e.m. ****P** < 0.01; ***P** < 0.05; Unpaired t-test with
885 Mann-Whitney test was used.

886 **Extended data, Fig. 6. Serum cytokine profile analysis.** Mice immunized with
887 Pool and T2 strategies presented increased serum levels of TNF α , IFN γ and IL-4
888 cytokine (**a**, **b**, **d**). IL-6 levels were only increased in **c)** infected-Pool and T1
889 immunized mice groups (Control, n = 5; Pool, n = 5; T1, n = 3; Inf, n = 5; Inf-Pool, n
890 = 5; Inf-T1, n = 3 and Control, n = 3; Pool, n = 4; T2, n = 5; Inf, n = 5; Inf-Pool, n =
891 5; Inf-T2, n = 5). Data are representative of three (Control, Pool, Inf and Inf-Pool
892 groups) and one (T1, T2, Inf-T1 and Inf-T2 groups) independent experiments.
893 Samples were collected before (Control, Pool, Inf-Pool and Inf-T1) and after
894 (Control, Pool, T2, Inf, Inf-Pool and Inf-T2) the behavioral evaluation. Data are mean
895 and s.e.m. ****P** < 0.01; ***P** < 0.05; Unpaired t-test with Mann-Whitney test was used.
896


897 **Fig. 1 Material & Methods. Experimental draw.** Groups of mice, infected or not
898 with *Plasmodium berghei* ANKA (*PbA*), were treated with chloroquine (25 mg / kg)
899 for seven days via gavage. After 14 days, they were subdivided into groups of
900 immunized (B and D) or non-immunized (A and D) mice, according to the
901 immunization strategies P (Pool), T1 (type 1 stimuli) and T2 (stimuli of type 2).
902 Subsequently, mice were evaluated in behavioral tasks for locomotivity, memory and
903 anxiety phenotype.
904

905 **Fig. 2 Material & Methods. Flow chart of immune stimuli and behavioral**
906 **assessment.** After infection and treatment with CQ, mice were categorized as
907 immunized or non-immunized, according to the immunization (P, T1 and T2)


908 strategies used. The dT and Influenza vaccines and pfMSP-3 were inoculated at the
909 same day, with three doses in different immunization pathways, with a 20-day
910 interval between inoculations. OVA was inoculated after the third dose of dT and
911 Influenza vaccines and pfMSP-3 protein was administered, three doses with a
912 seven-day interval between the inoculations. The ecLPS was inoculated after the
913 second dose of OVA, being two doses with an interval of ten days between them.
914 Assessment of performance on behavioral tasks started 77 days after chloroquine
915 treatment; 22 days after last inoculation of pfMSP-3 and dT and influenza vaccines;
916 7 days after last inoculation of Ovalbumin and 3 days after last inoculation with
917 ecLPS. The open field was performed to measure locomotivity, habituation memory
918 and anxiety phenotype, being performed in two sessions [training (OF1) and test
919 (OF2)]. Then, the new object recognition task was performed to measure long-term
920 memory, also in two sessions at consecutive days (training and testing). Finally, the
921 anxious behavior phenotype was specifically evaluated by the light-dark test,
922 performed in a unique session.
923

924 **Table 1.** Immune stimulus inoculation strategy: route, region, concentration, volume
925 and number of injections of immunogens.


Figure 1




Extended data, Figure 1




Extended data, Figure 2




Extended data, Figure 3




Extended data, Figure 4




Extended data, Figure 5




Extended data, Figure 6



Material & Methods, Figure 1



Material & Methods, Figure 2



Material & Methods, Table I

Immune Stimuli	Route	Region	Concentration	Volume	Inoculation
dT vaccine	Subcutaneous	Back	1/5 human dose	100 μ l	3
Influenza vaccine	Intramuscular	Quadriceps	1/5 human dose	100 μ l	3
pfMSP-3	Subcutaneous	Base Tail	10 μ g/mice	100 μ l	3
ecLPS	Intraperitoneal	Abdomen	0,1 mg/kg	100 μ l	2
Ovalbumin	Subcutaneous Intraperitoneal	Back and Abdomen	50 μ g	200 μ l	1 s.b.c. 2 i.p.